Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGX) and MDxHealth (MDXH)...

Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medline (MDLN), Protagonist Therapeutics (PTGX) and ...

Current Quarter	$-0.65	Next Quarter	$1.65
Current Year	$1.02	Next Year	$-1.59
QoQ Growth	+353.8%	YoY Growth	-255.9%
3Y EPS CAGR	+54.0%	Target Price	$111.77
Consensus	Buy	Upside	+7.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$103.75	0.00%	785.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTGX	$103.75	0%	785.11K
3
4
5
6

PTGX

PTGX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Protagonist Therapeutics Inc. Data in Excel

Get Protagonist Therapeutics Inc. Data in Excel